<a href="https://laohu8.com/S/IGC">IGC Pharma</a> Achieves 50% Enrollment Milestone in Phase 2 CALMA Trial for Alzheimer's Agitation Treatment
IGC Pharma, Inc. has announced the achievement of a 50% patient enrollment milestone in its Phase 2 CALMA clinical trial, which is focused on evaluating IGC-AD1 for treating agitation in Alzheimer's disease. This trial is a multicenter, double-blind, placebo-controlled, and randomized study. The company has expanded its geographic reach and enhanced patient diversity by adding new sites in Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico. The trial aims to complete recruitment by 2026. IGC-AD1, the company's proprietary formulation, combines low concentrations of delta-9 tetrahydrocannabinol $(THC)$ with another active pharmaceutical ingredient, targeting both agitation and potential disease-modifying effects in Alzheimer's patients. Results from the trial, which builds on promising Phase 1 and interim Phase 2 data, are expected to be fully analyzed upon trial completion in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076002) on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.